{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T18:33:42Z","timestamp":1710527622628},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,6,1]]},"DOI":"10.2169\/internalmedicine.0420-22","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T22:20:31Z","timestamp":1666131631000},"page":"1611-1615","source":"Crossref","is-referenced-by-count":1,"title":["A Hepatitis B Virus Reactivation Case Potentially Triggered by the Onset of Diffuse Large B Cell Lymphoma"],"prefix":"10.2169","volume":"62","author":[{"given":"Kentaro","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Aizu Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemichi","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ohta Nishinouchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Watahiki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ohta Nishinouchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Hazama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ohta Nishinouchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ohta Nishinouchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ohta Nishinouchi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Ohhira","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tsutsumi Y. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 7: 2344-2351, 2015.","DOI":"10.4254\/wjh.v7.i21.2344"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab plus steroid combination chemotherapy. J Gastroenterol 46: 9-16, 2011.","DOI":"10.1007\/s00535-010-0331-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Pattullo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol 22: 219-237, 2016.","DOI":"10.3350\/cmh.2016.0024"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32: 3736-3743, 2014.","DOI":"10.1200\/JCO.2014.56.7081"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hara T, Oka K, Iwai N, et al. Hepatitis B virus reactivation 55 months following chemotherapy including rituximab and autologous peripheral blood stem cell transplantation for malignant lymphoma. Intern Med 60: 417-421, 2021.","DOI":"10.2169\/internalmedicine.5678-20"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dominguez N, Manzano ML, Mu\u00f1oz R, et al. Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen. Leuk Lymphoma 56: 1160-1163, 2015.","DOI":"10.3109\/10428194.2014.947978"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Park JW, Kwak KM, Kim SE, et al. Differentiation of acute and chronic hepatitis B in IgM anti-HBc positive patients. World J Gastroenterol 21: 3953-3959, 2015.","DOI":"10.3748\/wjg.v21.i13.3953"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, Brody JD. Lymphoma: immune evasion strategies. Cancers 7: 736-762, 2015.","DOI":"10.3390\/cancers7020736"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103: 1755-1762, 2004.","DOI":"10.1182\/blood-2003-07-2594"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Aalaei-Andabili SH, Alavian SM. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine 30: 5595-5602, 2012.","DOI":"10.1016\/j.vaccine.2012.06.063"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Chen Y, Fang J, Chen X, Pan C, Liu X, Liu J. Effects of the Treg! Th17 cell balance and their associated cytokines in patients with hepatitis B infection. Exp Ther Med 9: 573-578, 2015.","DOI":"10.3892\/etm.2014.2104"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 178: 6840-6848, 2007.","DOI":"10.4049\/jimmunol.178.11.6840"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nakao M, Nakayama N, Uchida Y, et al. Nation-wide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol 53: 752-769, 2017.","DOI":"10.1007\/s00535-017-1394-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kamitsukasa H, Iri M, Tanaka A, et al. Spontaneous of hepatitis B virus (HBV) infection in patients with occult HBV infection. J Med Virol 87: 589-600, 2015.","DOI":"10.1002\/jmv.24115"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Morii S, Doi Y, Makita T, Takeda S, Saito S, Okabe S. A case of <i>de novo<\/i> hepatitis B associated with statin administered at 64 months later following allogeneic hematopoietic stem cells transplantation. Kanzo 56: 661-667, 2015 (in Japanese).","DOI":"10.2957\/kanzo.56.661"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6: 358-370, 2006.","DOI":"10.1038\/nri1839"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 197: 829-839, 2008.","DOI":"10.1016\/j.atherosclerosis.2007.07.031"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tang TT, Song Y, Ding YJ, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res 52: 1023-1032, 2011.","DOI":"10.1194\/jlr.M010876"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Hepatitis B virus reactivation in a patient with nonalcoholic steatohepatitis 41 months after rituximab-containing chemotherapy. Intern Med 58: 375-380, 2019.","DOI":"10.2169\/internalmedicine.1587-18"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Nonalco- holic fatty liver disease and statins. Metabolism 64: 1215-1223, 2015.","DOI":"10.1016\/j.metabol.2015.07.003"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Van Rooyen DM, Gan LT, Yeh MM, et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 59: 144-152, 2013.","DOI":"10.1016\/j.jhep.2013.02.024"},{"key":"22","unstructured":"22. Tsujioka T, Kishimoto M, Kondo T, et al. The impact of serum soluble interleukin-2 receptor levels on the diagnosis of malignant lymphoma. Kawasaki Med J 37: 19-27, 2011."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Allan JN, Furman RR. Current trends in the management of Richer&apos;s syndrome. Int J Hematol Oncol 7: IJH09, 2019.","DOI":"10.2217\/ijh-2018-0010"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tsimberidou AM, O&apos;Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richer&apos;s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem cell transplantation. J Clin Oncol 24: 2343-2351, 2006.","DOI":"10.1200\/JCO.2005.05.0187"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/11\/62_0420-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T03:31:18Z","timestamp":1685763078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/11\/62_0420-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0420-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"article-number":"0420-22"}}